In this special edition of Fact Check Friday, we’re focusing on why disclosing discounts and rebates negotiated between payers and biopharmaceutical manufacturers won’t help patients or lower out-of-pocket costs.
For many of America’s biopharmaceutical researchers and scientists, seeing the positive effects of their work on the lives of patients is what encourages them to keep striving.
Dr. Al Sandrock, chief medical officer at Biogen, recently shared his experiences working in the biopharmaceutical industry and how first-hand accounts from patients motivate him every day.
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we spotlight a new website from The Medication Adherence Alliance, an organization comprised of representatives from consumer advocacy groups, community health providers, non-profit groups, the academic community, decision-making government officials and industry representatives.
Every year, the Trustees of the Social Security and Medicare trust funds release an annual report on the current and projected status of the two programs. The 2016 report on Medicare was released last week. Here are a few important things in the report:
In case you missed it, PwC Health Research Institute’s (HRI) Medical Cost Trend: Behind the Numbers 2017 report highlights medicine spending is “still a relatively small portion of overall health spending and, as such, concerns of ever-increasing cost growth from new cures may trigger false alarms.”
Topics: drug cost
Access to prescription medicines is critical to help patients manage their chronic conditions and maximize quality of life. Unfortunately, even with insurance coverage, many patients still struggle to get the medicines they need due to high out-of-pocket costs and other plan restrictions. We looked at the burden on patients with health insurance exchange coverage in 2014 and 2015. Now, we’re taking a look at 2016 coverage.
Topics: Access, Cystic Fibrosis, health insurance, HIV/AIDS, Burden on Patients, Multiple Sclerosis, exchanges, Mental Health, Oncology, Access Better Coverage, ABCs of Coverage, Policy Solutions, Empower Consumers
Ask About Adherence is a blog series featuring Q&A’s with experts in medication adherence. In this post, we speak with Marisa Schauerhamer, a 2016 PhRMA Foundation Young Investigator Adherence grantee, about her research on how value-based insurance design affects medication adherence for patients with diabetes.
Back in April, we previewed MedPAC’s recommendations and expressed concern and opposition to the sweeping recommended changes to Part D that taken together could harm beneficiaries by eroding coverage and protections for many of the most vulnerable enrollees in the program.
America’s biopharmaceutical research companies are committed to developing new treatments and cures that improve health and save patient lives. Jen O’Neil, principal oncology scientist at Merck, recently shared her story about the importance of collaboration in the research and development process and how this environment inspires her despite the setbacks along the way.
The United States is not only falling behind other countries on many key science, technology, engineering and mathematics (STEM) indicators, but our public investment in STEM education has steadily declined at the same time that other countries—including our biggest global competitors—are making substantial investments. The choices we make now will impact America’s global competitiveness and economic growth for years to come.